Skip to content

Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-511104-16-00
Enrollment
40
Registered
2024-02-28
Start date
Unknown
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Brief summary

The proportion of subject with PSMA- and/or FAPI-positive metastases and number of metastases

Detailed description

The proportion of detected metastasis with 18F-FAPI-74 PET/CT compared to the 18F-DCFPyL PET/CT, The sensitivity, specificity, accuracy, and area under the receiver-operating characteristic curve (AUC) values of 18F-DCFPyL PET/CT and 18F-FAPI-74 PET/CT in detecting metastatic subjects

Interventions

DRUG18F-DCFPyL CURIUM
DRUG1000 MBq/mL solution for injection

Sponsors

Turku University Hospital
Lead SponsorOTHER

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The proportion of subject with PSMA- and/or FAPI-positive metastases and number of metastases

Secondary

MeasureTime frame
The proportion of detected metastasis with 18F-FAPI-74 PET/CT compared to the 18F-DCFPyL PET/CT, The sensitivity, specificity, accuracy, and area under the receiver-operating characteristic curve (AUC) values of 18F-DCFPyL PET/CT and 18F-FAPI-74 PET/CT in detecting metastatic subjects

Countries

Finland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026